Confirming a diagnosis of Spinal Muscular Atrophy (SMA) requires integrating clinical suspicion with targeted neurodiagnostic investigations
Genetic testing serves as the definitive diagnostic gold standard
In addition to genetic testing, several supportive diagnostic modalities provide insight into motor neuron and muscle integrity:
Serum Creatine Phosphokinase (CPK): Serum CPK levels in SMA are typically normal to slightly elevated (up to 2 times normal in acute forms)
. However, in chronic, milder forms like SMA Type III, CPK levels can occasionally reach up to 10 times the normal limit due to ongoing secondary muscle changes . Electromyography (EMG): EMG reveals evidence of chronic denervation and reinnervation
. Classic findings include spontaneous motor unit action potentials, fibrillations, positive sharp waves, and fasciculations (more readily observed in Types II and III) . Motor unit action potentials (MUAPs) exhibit increased amplitude and prolonged duration with reduced recruitment patterns . Nerve Conduction Studies: Sensory nerve action potentials (SNAPs) remain normal, confirming that the sensory pathways are spared
. Compound muscle action potentials (CMAPs) may show reduced amplitudes with normal conduction velocities . Muscle Biopsy: When performed, histopathological examination shows pathognomonic grouped atrophy
. Large areas of small, atrophic Type I and Type II muscle fibers alternate with hypertrophied muscle fibers, contrasting with the normal checkerboard distribution of fiber types .